GAITHERSBURG, Md., Aug. 12, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that, as a result of
the completion of the spin-off of Aptevo Therapeutics, the conversion rate for the company’s 2.875% Convertible Senior Notes due
2021 has been adjusted to 32.3860 shares of common stock per $1,000 principal amount, which is equivalent to a conversion price of
approximately $30.88 per share of common stock, effective after market close on August 12, 2016.
The adjustment to the conversion rate was made pursuant to section 14.04(c) of the Indenture for the senior notes dated January
29, 2014, which applies to spin-off transactions.
The conversion rate was previously 30.8821 shares of common stock per $1,000 principal amount of the senior notes, which is
equivalent to an initial conversion price of approximately $32.38 per share of common stock.
About Emergent BioSolutions
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance
life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well
as emerging infectious diseases. Through our work, we envision protecting and enhancing 50 million lives with our products by
2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 BurrowsR@ebsi.com Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3394 SchmittT@ebsi.com
